Nanexa AB - Home

VISION & MISSION

Nanexa will be a world leading drug development company for Long Acting Injectables, developing a new generation of innovative drug products enabled by our unique PharmaShell® technology”

In its state-of-the-art pilot plant and labs in Uppsala, Nanexa runs the development of own product projects and collaborative projects with other pharmaceutical companies, based on the PharmaShell® system.

PRESSRELEASES

27 August, 2024

Nanexa publishes interim report for January-June 2024

NEX-22 clinical trial initiated and proceeding with dose escalation as planned

28 June, 2024

Nanexa appoints new Chief Financial Officer

Nanexa AB (publ) today announces that Cecilia Danckwardt-Lillieström will take over as Chief Financial Officer as of September 1, 2024, as the current CFO Björn Svanström has chosen to leave the company.